The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Population-based analysis of a novel prognostic model for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA).
Arun Azad
No relevant relationships to disclose
Renee Lester
No relevant relationships to disclose
Raya Leibowitz-Amit
No relevant relationships to disclose
Anthony Michael Joshua
Research Funding - Janssen-Ortho
Daniel Yick Chin Heng
No relevant relationships to disclose
Bernhard J. Eigl
Other Remuneration - Janssen
Kim N. Chi
Consultant or Advisory Role - Janssen
Research Funding - Janssen-Ortho